Verona Pharma reported $5.6 million in net sales for Ohtuvayre™ (ensifentrine) in Q3 2024, marking a strong start to its US launch for COPD maintenance treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.